Fundraising Fox

Syntis Bio

Boston, US · Founded 2022 · Delaware corporation · 5 known investors

syntis.bio ↗

Syntis Bio develops bioengineered polymer coatings for oral drug delivery, specifically targeting gastrointestinal tissues to enhance bioavailability of therapeutics in low-resource settings. The company's SYNT™ technology uses mussel-inspired materials to deliver complex biologics like enzymes and peptides to the small intestine.

BiotechDeep TechDigital Healthin /syntis-bio@syntisbio

Founders & leadership

RD
Rahul DhandaExecutive Officer, Director
CG
Carlo Giovanni TraversoDirector
RL
Robert LangerDirector
TB
TEYMOUR BOUTROS-GHALIDirector
TB
Teymour Boutros-GhaliDirector
MM
Martin MadausDirector

Investors · 5

Bill & Melinda Gates Foundation✓ verifiedSeattle
Bold Capital PartnersSanta Monica
Cerity Partners VenturesNew York
Portal InnovationsChicago
Safar PartnersCambridge

Reported raises · per SEC filings

Form D private placements
▶$25MraisedJul 2025 · 12 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Chenny ZhangDirector
  • Martin MadausDirector
  • Carlo Giovanni TraversoDirector
  • Robert LangerDirector
  • Teymour Boutros-GhaliDirector
  • Teymour Boutros-GhaliDirector
  • Rahul DhandaExecutive Officer, Director
  • Michael NannizziDirector
Offering amount
$26.5M
Amount sold
$25M
First sale
Jun 2025
Incorporated
Corporation, Delaware, 2022
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$6.3MraisedJan 2025 · 9 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Martin MadausDirector
  • Rahul DhandaExecutive Officer, Director
  • Carlo Giovanni TraversoDirector
  • Teymour Boutros-GhaliDirector
  • Robert LangerDirector
Offering amount
$9M
Amount sold
$6.3M
First sale
Dec 2024
Incorporated
Corporation, Delaware, 2022
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$15.4MraisedJan 2023 · 15 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • MARTIN MADAUSDirector
  • RAHUL K. DHANDAExecutive Officer, Director
  • CARLO GIOVANNI TRAVERSODirector
  • ROBERT LANGERDirector
  • TEYMOUR BOUTROS-GHALIDirector
Offering amount
$15.4M
Amount sold
$15.4M
First sale
Aug 2022
Incorporated
Corporation, Delaware, 2022
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.